Xintela AB

Equities

XINT

SE0007756903

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 12:00:00 2024-06-10 EDT			5-day change	1st Jan Change
0.258 ^SEK	+2.38%		-1.53%	-4.80%

05-24	Xintela AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
05-23	Xintela and EQGen Biomedical to Collaborate to Develop EQSTEM Stem Cell Treatment for Horses	CI

Claes Post Decides Not to Stand for Re- Election as Board Member of Xintela AB

April 26, 2019 at 02:30 am

The Board of Xintela AB (publ) announced that board member Claes Post has decided not to stand for re- election. The Board announced that Peter Edman has been nominated for election to the Board at the annual general meeting on the 27th of May 2019.

Latest news about Xintela AB

Xintela AB Reports Earnings Results for the First Quarter Ended March 31, 2024	05-24	CI
Xintela and EQGen Biomedical to Collaborate to Develop EQSTEM Stem Cell Treatment for Horses	05-23	CI
Xintela AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-28	CI
Xintela Names New Chief Scientific Officer	02-20	MT
Xintela Appoints Lucienne Vonk as Chief Scientific Officer	02-19	CI
Xintela AB Announces First Patient Dosed in It's Clinical Study on Difficult-To-Heal Leg Ulcers	12-21	CI
Xintela Publishes Efficacy Results with EQSTEM from Preclinical Equine OA Study	12-20	CI
Xintela AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-24	CI
Xintela's Stem Cell Product, Xstem, Assessed as Safe At All Dose Levels in Knee Osteoarthritis Clinical Study	23-10-13	CI
Xintela AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-30	CI
Xintela Receives Product Patent in USA for Chondrocyte-Based Products	23-08-15	CI
Xintela Completes XSTEM Dosing at Third and Final Dose Level in Knee Osteoarthritis Clinical Study	23-06-22	CI
Xintela AB Announces Clinical Study with XSTEM for Knee Oeoarthritis Makes Good Progress	23-06-01	CI
Xintela AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-25	CI
Xintela AB Initiates Last Dose Level in Knee Osteoarthritis Study	23-05-02	CI
Xintela Starts Last Dose Level of Xstem in Knee Osteoarthritis Clinical Study	23-04-13	CI
Xintela AB Completes Dosing of XSTEM Second Dose Level in Knee Osteoarthritis Clinical Study	23-03-03	CI
Xintela AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-02-24	CI
Xintela and Northx Biologics Sign Collaboration Framework Agreement	22-12-14	CI
Xintela AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-25	CI
Xintela AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-25	CI
Xintela Starts Next Dose Level of Xstem in Knee Osteoarthritis Clinical Study	22-11-09	CI
Xintela Completes Dosing of Xstem First Dose Level in Knee Osteoarthritis Clinical Study	22-09-30	CI
Xintela AB Appoints Peter Ekolind as Acting CEO, Effective October 1, 2022	22-09-22	CI
Xintela AB Starts Clinical Study with XSTEM for Difficult-To-Heal Leg Ulcers	22-09-20	CI

Chart Xintela AB

Duration

Period

More charts

Company Profile

Xintela AB (Xintela) is a Sweden-based biomedical company engaged in the fields of regenerative medicine and cancer, with particular focus on cartilage damage and brain tumors. In the field of regenerative medicine, the Company focuses on cartilage damage and osteoarthritis, and in the field of brain tumors, its focuses on the development of a treatment for glioblastoma, an aggressive tumor. The Company has developed therapeutic antibodies, which bind to cancer cells. It has also developed XINMARK, a marker technology which consists of specific proteins, which work as recognition flags on the surface of certain cells. The markers make it possible to identify and select certain types of stem cells which can develop into cartilage cells.

Sector

Biotechnology & Medical Research

Calendar

2024-08-29 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
XINTELA AB	-4.80%	13.56M
MODERNA, INC.	+48.31%	57.87B
LONZA GROUP AG	+41.65%	40.25B
IQVIA HOLDINGS INC.	-7.16%	39.94B
CELLTRION, INC.	-5.96%	28.54B
ICON PUBLIC LIMITED COMPANY	+12.22%	26.4B
ALNYLAM PHARMACEUTICALS, INC.	-20.16%	19.33B
MEDPACE HOLDINGS, INC.	+29.90%	12.4B
BIO-TECHNE CORPORATION	-0.71%	12.23B
UNITED THERAPEUTICS CORPORATION	+24.22%	12.2B

Other Biotechnology & Medical Research